当前位置： SCI文献检索 > CARDIOVASCULAR DRUGS AND THERAPY期刊下所有文献 > Use of milrinone in cardiac surgical patients.

Use of milrinone in cardiac surgical patients.

Abstract：

:Milrinone is shown in 10 patients to be a valuable pharmacological bridge to heart transplantation; it can stabilize and improve decompensated chronic heart failure (CHF) in cases where the response to beta-agonists is inadequate. One patient who had suffered an acute myocardial infarction with heart failure resistant to vasodilators, beta-agonists, and balloon counterpulsation was stabilized with milrinone for 21 days. He was then maintained on ACE inhibitors until heart transplantation 3 months later. The other nine patients with severe decompensated CHF were stabilized on milrinone for between 11 and 51 days. Seven of them received a donor heart. Two patients died of bacteremic shock and terminal heart failure before a suitable organ could be found (31 and 51 days). All patients were clinically improved within 48 hours of the addition of IV milrinone to their therapy. In 55 patients following cardiac surgery, the efficacy and safety of milrinone in the treatment of low cardiac output states is demonstrated. Milrinone has a useful role in the management of patients with circulatory failure both before and after cardiac surgery, and this paper reviews the relevant current literature.

journal_name

Cardiovasc Drugs Ther

journal_title

Cardiovascular drugs and therapy

authors

Sherry KM,Locke TJ

doi

10.1007/BF00877820

subject

Has Abstract

pub_date

1993-08-01 00:00:00

pages

671-5

issue

4

eissn

0920-3206

issn

1573-7241

journal_volume

7

pub_type

杂志文章,评审

相关文献

CARDIOVASCULAR DRUGS AND THERAPY文献大全
  • Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration.

    abstract：:The aim of this study was to compare the pharmacokinetics and antiarrhythmic activity of dihydroquinidine and quinidine in 14 patients (11 men, 3 women, aged 28 to 67 years) with heart disease and chronic, stable, high-frequency premature ventricular beats (PVB) (greater than 100/hr). A randomized, double-blind, cross...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF00054209

    authors： Chimienti M,Regazzi MB,La Rovere MT,Salerno JA,Previtali M,Montericcio V,Rondanelli R,Montemartini C

    更新日期：1988-12-01 00:00:00

  • Effects of short- and long-term administration of nifedipine on serum lipoprotein metabolism in patients with mild hypertension.

    abstract：:The effects of short- and long-term administration of nifedipine on serum lipids, lipoproteins, and apolipoproteins (apo) were studied. Administration of nifedipine capsule for 4 months significantly decreased triglycerides and increased the HDL2 cholesterol and the HDL2/HDL3 cholesterol ratio. No significant changes ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF02018313

    authors： Sasaki J,Arakawa K

    更新日期：1990-08-01 00:00:00

  • Azelnidipine inhibits H2O2-induced cell death in neonatal rat cardiomyocytes.

    abstract：PURPOSE:Oxidative stress plays an important role in the pathogenesis of cardiovascular diseases. Azelnidipine is a novel dihydropyridine calcium channel blocker. Several studies have demonstrated that some dihydropyridine calcium channel blockers have antioxidant effects. We evaluated the antioxidant effects of azelnid...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-007-6008-4

    authors： Koyama Y,Takeishi Y,Takahashi H,Shishido T,Arimoto T,Niizeki T,Harada M,Suzuki S,Kitahara T,Sasaki T,Kubota I

    更新日期：2007-02-01 00:00:00

  • Association of Regulatory Genetic Variants for Protein Kinase Cα with Mortality and Drug Efficacy in Patients with Heart Failure.

    abstract：PURPOSE:Protein kinase C alpha (gene: PRKCA) is a key regulator of cardiac contractility. Two genetic variants have recently been discovered to regulate PRKCA expression in failing human heart tissue (rs9909004 [T → C] and rs9303504 [C → G]). The association of those variants with clinical outcomes in patients with hea...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-019-06909-6

    authors： Luzum JA,Ting C,Peterson EL,Gui H,Shugg T,Williams LK,Li L,Sadee W,Wang D,Lanfear DE

    更新日期：2019-12-01 00:00:00

  • Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline.

    abstract：PURPOSE:The ischemic/bleeding trade-off of continuing dual antiplatelet therapy (DAPT) beyond 1 year after PCI for patients with high thrombotic risk (HTR) as endorsed by 2018 ESC/EACTS myocardial revascularization guidelines remain unknown. METHODS:Patients undergoing coronary stenting between January 2013 and Decemb...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-020-07030-9

    authors： Wang HY,Dou KF,Wang Y,Yin D,Xu B,Gao RL

    更新日期：2020-10-01 00:00:00

  • The effects of calcium antagonists on extracellular potassium accumulation during global ischaemia in isolated perfused rat hearts.

    abstract：:The effects of equipotent concentrations of diltiazem, verapamil, and nifedipine upon the accumulation of extracellular potassium [K+]out and the left ventricular pressure (LVP) were studied during global ischemia in isolated perfused rat hearts. Measurement of [K+]out and LVP were performed in two series of experimen...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF00143532

    authors： Heijnis JB,Coronel R,van Zwieten PA

    更新日期：1991-12-01 00:00:00

  • Addition of chlorthalidone to slow-release nifedipine in the treatment of arterial hypertension: a controlled study versus placebo.

    abstract：:The use of calcium antagonists and diuretics in combination for treatment of hypertension is controversial. In a single-blind study 16 patients (8 men, 8 women, age range 39 to 62 years) with primary hypertension of mild to moderate degree were given slow-release nifedipine 20 mg twice daily for 6 weeks, thereafter ei...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF02125751

    authors： Ferrara LA,Marotta T,Pasanisi F,Mastranzo P,Mancini M

    更新日期：1988-03-01 00:00:00

  • Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases.

    abstract：PURPOSE:This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the Taiwan setting. METHODS:We constructed a Markov model to project the lifetime direct medical costs and quality-adjusted life-years of both the...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-020-07059-w

    authors： Lee MC,Liao CT,Toh HS,Chou CC,Chang WT,Chen ZC,Wu WS,Yu T,Strong C

    更新日期：2020-09-10 00:00:00

  • Torsades de pointes: arrhythmia, syndrome, or chimera?

    abstract：:Although torsades de pointes is not a tightly demarcated entity, the diagnosis has important clinical implications. The concept should be retained. ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF03029821

    authors： Millar RN

    更新日期：1991-02-01 00:00:00

  • Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis.

    abstract：PURPOSE:Platelets are essential for primary hemostasis; however, platelet activation also plays an important proinflammatory role. Inflammation promotes the development of cardiac fibrosis and heart failure induced by hypertension. In this study, we aimed to determine whether inhibiting platelet activation using clopid...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-013-6471-z

    authors： Jia LX,Qi GM,Liu O,Li TT,Yang M,Cui W,Zhang WM,Qi YF,Du J

    更新日期：2013-12-01 00:00:00

  • Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant.

    abstract：PURPOSE:Rivaroxaban, an oral anticoagulant, undergoes the metabolism mediated by human cytochrome P450 (CYP). The present study is to quantitatively analyze and compare the contributions of multiple CYPs in the metabolism of rivaroxaban to provide new information for medication safety. METHODS:The metabolic stability ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-020-07129-z

    authors： Zhao T,Chen Y,Wang D,Wang L,Dong P,Zhao S,Wang C,Meng Q,Sun H,Liu K,Wu J

    更新日期：2021-01-07 00:00:00

  • Acute effects of celiprolol on angiographically normal and stenotic coronary arteries.

    abstract：:Unselective and beta 1-selective beta-blockers may induce vasoconstriction of normal and stenotic epicardial coronary arteries. To analyze the influence of the "vasodilatory" beta-blocker celiprolol on coronary vasomotility, 0.4 mg celiprolol/kg were intravenously infused over 4 minutes in 13 patients with coronary ar...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1007780713915

    authors： Jost S,Hausmann D,Lippolt P,Sturm M

    更新日期：1997-04-01 00:00:00

  • Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspective.

    abstract：:The calcium antagonist (CA) controversy has been fueled in part by disagreements among scientists and clinicians over the scientific documentation required for drugs used to treat lifelong conditions. From a public health perspective, there are three unanswered questions: (1) Does long-term use of CAs convey health be...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF00051111

    authors： Furberg CD,Psaty BM

    更新日期：1996-09-01 00:00:00

  • Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury.

    abstract：PURPOSE:To evaluate whether aleglitazar (Ale), a dual PPARα/γ agonist, has additive effects on myocardial protection against ischemia-reperfusion injury. METHODS:Human cardiomyocytes (HCMs), cardiomyocytes from cardiac-specific PPARγ knockout (MCM-PPARγ (CKO) ) or wild type (MCM-WT) mice were incubated with different ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-016-6650-9

    authors： Qian J,Chen H,Birnbaum Y,Nanhwan MK,Bajaj M,Ye Y

    更新日期：2016-04-01 00:00:00

  • Encainide.

    abstract：:Encainide is a class IC antiarrhythmic agent having little or no effect on action-potential duration or maximum diastolic potential but decreasing the maximum rate of phase O depolarization as well as increasing atrial and ventricular effective refractory periods. In intact animals or humans, encainide increases the A...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF01857621

    authors： Antonaccio MJ,Gomoll AW,Byrne JE

    更新日期：1989-10-01 00:00:00

  • Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.

    abstract：AIMS:Rapid restoration of sinus rhythm using pharmacological cardioversion is commonly indicated in patients with symptomatic recent-onset atrial fibrillation (AF). The objectives of this large, international, multicenter observational study were to determine the safety and effectiveness of intravenous (IV) vernakalant...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-020-07103-9

    authors： Lévy S,Hartikainen J,Ritz B,Juhlin T,Carbajosa-Dalmau J,Domanovits H

    更新日期：2020-11-18 00:00:00

  • Preconditioning myocardium with ischemia.

    abstract：:Preconditioning and stunning are the chief adaptive changes induced in myocardium by a brief episode of reversible ischemia followed by arterial reperfusion. In the dog heart, both coexist for a period of at least 20 minutes of reperfusion, but after 120 minutes of reflow, preconditioning is much diminished, while stu...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF00053555

    authors： Jennings RB,Murry CE,Reimer KA

    更新日期：1991-10-01 00:00:00

  • Combined treatment with ramipril and metoprolol prevents changes in the creatine kinase isoenzyme system and improves hemodynamic function in rat hearts after myocardial infarction.

    abstract：:Beneficial effects of monotherapy with ACE inhibitors or beta-blockers on hemodynamic function after myocardial infarction are well known. Until now, the effects of combined treatment on cardiac function and energy metabolism have been poorly described. This study examines the effects of combined ramipril and metoprol...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1023/a:1007846311040

    authors： Theres HP,Wagner KD,Romberg D,Feig C,Strube S,Leiterer KP,Günther J,Stangl K,Baumann G,Schimke I

    更新日期：2000-12-01 00:00:00

  • KT-362 related effects on intracellular calcium release and associated clinical potential: arrhythmias, myocardial ischemia, and hypertension.

    abstract：:The following discourse addresses the pharmacologic profile of KT-362, its clinical potential as an anti-arrhythmic agent with associated hypotensive effects, as well as its additional related potential in myocardial ischemia and related sequellae, and the specific cellular actions that may be responsible for these po...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF02018262

    authors： Hester RK,Shibata S

    更新日期：1990-10-01 00:00:00

  • Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition.

    abstract：:Cilazapril, an angiotensin-converting enzyme inhibitor, and mibefradil, a selective T-type voltage-operated calcium channel blocker, have been shown to prevent neointima formation after vascular injury. The goal of the present study was to evaluate the mechanism of action of both drugs. For this purpose, the influence...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF00823586

    authors： Schmitt R,Clozel JP,Iberg N,Bühler FR

    更新日期：1996-05-01 00:00:00

  • Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II).

    abstract：AIMS:We evaluated a generic quality of life (QoL) Functional Status Questionnaire (FSQ), in patients with chronic heart failure (CHF). The FSQ assesses the 3 main dimensions of QoL: physical functioning, mental health and social role. It also includes 6 single item questions about: work status, frequency of social inte...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10557-011-6284-x

    authors： Gallanagh S,Castagno D,Wilson B,Erdmann E,Zannad F,Remme WJ,Lopez-Sendon JL,Lechat P,Follath F,Höglund C,Mareev V,Sadowski Z,Seabra-Gomes RJ,Dargie HJ,McMurray JJ

    更新日期：2011-02-01 00:00:00

  • Does digoxin have a place in the treatment of the child with congenital heart disease?

    abstract：:The place of digoxin in the pediatric cardiologist's armamentarium remains uncertain. As an antiarrhythmic, its use in the Wolff-Parkinson-White syndrome is obsolete, but it remains useful in the treatment of the chronic atrial fibrillation seen in some patients postoperatively and in children with dilated cardiomyopa...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF01881525

    authors： Redington AN,Carvalho JS,Shinebourne EA

    更新日期：1989-03-01 00:00:00

  • The costs of treating hypertension.

    abstract：:Recent surveys in the U.S. have reported, for the first time, that a significant number of patients with hypertension are finding that the cost of medication and treatment in general is an obstacle to treatment. The cost of management of hypertension can be contained if: a) the diagnostic workup is kept simple (this d...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF01857624

    authors： Moser M

    更新日期：1989-10-01 00:00:00

  • Effects of almokalant, a class III antiarrhythmic agent, on supraventricular, reentrant tachycardias. Almokalant Paroxysmal Supraventricular Tachycardia Study Group.

    abstract：:The aim of the present study was to investigate the effects of almokalant on sustained reentrant supraventricular tachycardias. Reentrant tachycardias were induced, using transesophageal atrial stimulation, in 82 patients with atrioventricular reentrant tachycardia (n = 54) or AV nodal reentrant tachycardia (n = 28). ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1007761825414

    authors： Darpö B,Edvardsson N

    更新日期：1997-07-01 00:00:00

  • Differential ability of human endothelial cells to internalize and express exogenous DNA.

    abstract：:Vascular endothelium gene expression regulates blood-vessel wall interactions, vascular permeability, smooth muscle cell growth and tone. The possibility to introduce exogenous DNA or RNA sequences in endothelial cells represents a novel therapeutic approach of vascular disease. The aim of the work was to investigate ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1023/a:1011154616992

    authors： Colombo MG,Citti L,Basta G,De Caterina R,Biagini A,Rainaldi G

    更新日期：2001-01-01 00:00:00

  • Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse.

    abstract：PURPOSE:Acute myocardial infarction (AMI) drives an intense inflammatory response that contributes to infarct healing and cardiac remodeling. Recently, different studies have identified a role of interleukin-1 (IL-1) in the development of adverse cardiac remodeling. However, in animal models of AMI IL-1 has been shown ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-012-6389-x

    authors： Toldo S,Schatz AM,Mezzaroma E,Chawla R,Stallard TW,Stallard WC,Jahangiri A,Van Tassell BW,Abbate A

    更新日期：2012-06-01 00:00:00

  • The efficacy of nifedipine and acebutolol in coronary artery disease assessed by radionuclide ventriculography.

    abstract：:The efficacy of a fixed combination of 10 mg nifedipine and 100 mg acebutolol was tested in 21 patients with angiographically proven coronary artery disease (CAD). Ejection fraction (EF), emptying and filling rate (VS and VD), and end-systolic volume (ESV) were assessed by means of radionuclide ventriculography at res...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF00148473

    authors： Bauer R,Busch U,Lutilsky L,van de Flierdt E,Langhammer HR,Pabst HW

    更新日期：1989-06-01 00:00:00

  • Unique Aspects of Coronary Artery Disease in Indian Women.

    abstract：PURPOSE:Epidemiologic and clinical research suggests important gender-related differences in the prevalence, presentation, associated conventional and non-conventional risk factors, management and outcomes of coronary heart disease (CHD) patients. Adequate data is not available for Indian population where prevalence of...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-015-6594-5

    authors： Bhatt P,Parikh P,Patel A,Parikh R,Patel A,Mehta JL,Parikh K

    更新日期：2015-08-01 00:00:00

  • Enoximone: true inotropic effects? Do they cause ischemia? Analysis of end-systolic pressure-volume relations using the conductance (volume) catheter technique.

    abstract：:True positive inotropy of enoximone is hard to prove clinically. It could increase the risk of myocardial ischemia when used in coronary artery disease (CAD). The analysis of the end-systolic pressure-volume relationship (ESPVR) as a load-independent parameter of the contractile left ventricular function (LVF) allows ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF02018269

    authors： Thormann J,Hueting J,Kremer P,Wissemann J,Mitrovic V,Dieterich HA,Schlepper M

    更新日期：1990-10-01 00:00:00

  • Effect of propranolol on ventricular repolarization and refractoriness: role of beta-blockade versus direct membrane effects.

    abstract：:The purpose of this study was to define the role of beta-adrenergic blockade and direct membrane effects in the ability of dl-propranolol to alter ventricular repolarization and refractoriness in the intact heart. The effective refractory period (ERP) and the local Q-T interval were measured at an epicardial site in t...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF02125746

    authors： Euler DE,Scanlon PJ

    更新日期：1988-03-01 00:00:00